Peptide Profile
Ularitide
A synthetic natriuretic peptide designed to help your heart pump better and remove excess fluid when you need it most.
Dose Range
As prescribed-As prescribedmg
Frequency
Once daily
Route
Intravenous infusion
Cycle Length
Ongoing/indefinite
Onset
Moderate (1-2 weeks)
Evidence
Strong
Compound Profile
Scientific & Efficacy Data
C145H234N52O44S3
Molecular Formula
3505.9
Molecular Weight
6-7 minutes (in circulation)
Half-Life
100% (intravenous administration)
Bioavailability
Not publicly assigned (proprietary compound)
CAS #
16132416
PubChem ID ↗
Developed By · 2003
Noscira Research Team
Noscira (Spanish biotech)
Primary Benefits
Directly improves heart function and blood flow by relaxing vessels and reducing cardiac workload during emergencies.
Naturally increases water and sodium excretion while maintaining critical electrolyte levels for heart health.
Supports kidney function during heart stress rather than damaging it, unlike some other emergency heart treatments.
Amino Acid Sequence
SLRPGGA(32 amino acids total - Urodilatin structure)Dosing
How much
do I take?
Timing
Best time to take
Ularitide is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.
With food?
IV administration of Ularitide is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.
If stacking
Ularitide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Managing acute heart failure symptoms and fluid overload
Ularitide is particularly well-suited for individuals focused on managing acute heart failure symptoms and fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving oxygen delivery when your heart can't pump efficiently
Ularitide is particularly well-suited for individuals focused on improving oxygen delivery when your heart can't pump efficiently. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Protecting kidney function in critical heart patients
Ularitide is particularly well-suited for individuals focused on protecting kidney function in critical heart patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Hypotension (dangerously low blood pressure)
- ×Cardiogenic shock without proper monitoring
- ×Severe renal dysfunction in some cases
- ×Allergy to synthetic peptides
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Ularitide use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Ularitide vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Ularitide is a recombinant B-type natriuretic peptide approved in Europe for acute heart failure with safety data from Phase 3 trials showing favorable tolerability compared to placebo and nesiritide. Hypotension is the primary dose-limiting adverse effect, requiring baseline blood pressure assessment and careful hemodynamic monitoring during IV infusion. Natriuretic peptide class risks include worsening renal function in some patients and hypokalemia (electrolyte abnormalities from enhanced diuresis), necessitating electrolyte monitoring during acute phase therapy.
Phase 3 PROTECT trial and European post-market surveillance provide moderate safety evidence in acute decompensated heart failure populations. Not approved in the United States, but used extensively in Europe since 2007. Long-term chronic heart failure safety data beyond acute infusion phase are limited; mechanism of action (natriuretic/vasodilatory) suggests favorable renal and hemodynamic profile compared to inotropes, but clinical outcomes data remain incomplete.
Common Side Effects
Experienced by some users
Dizziness or lightheadedness
Occurs in 20-30% of patients during the infusion, primarily during first 30-60 minutes. Relates directly to ularitide's vasodilatory effects causing blood vessel relaxation. Dizziness is more pronounced when sitting or standing; typically resolves when lying flat. Most patients adapt within the first 1-2 hours as the body compensates for lower blood pressure.
Management: Maintain supine or semi-recumbent positioning during infusion. Use continuous blood pressure monitoring to guide dose adjustments. Rise slowly if needing to sit up. Most dizziness resolves without specific intervention. Inform your ICU team immediately if dizziness is severe or accompanied by chest pain or syncope.
Low blood pressure (hypotension)
Blood pressure typically drops 20-35 mmHg during ularitide infusion in 40-50% of patients, which is the intended therapeutic effect for acute heart failure. Hypotension is dose-dependent and can be titrated. Excessive drops below systolic 80-90 mmHg require dose reduction. Monitoring and dose adjustment prevent dangerous hypotension while maintaining therapeutic benefit.
Management: Arterial line or frequent cuff measurements monitor pressure continuously. Dosing is adjusted to balance hemodynamic improvement with maintaining adequate perfusion pressure. IV fluids and electrolyte management support blood pressure. Your ICU team carefully titrates ularitide to achieve diuresis while preventing symptomatic hypotension. Vasopressors are used if needed.
Headache
Occurs in 15-20% of patients within first 1-2 hours of infusion. Relates to blood pressure changes, vasodilation, and fluid shifts. Headaches are typically mild and resolve within 2-4 hours as the body adjusts. More common in patients with baseline hypertension or rapid blood pressure drops.
Management: Most headaches resolve without intervention as vasodilation stabilizes. Supine positioning and hydration status adjustment may help. Pain medication is available if needed but rarely necessary. Continued monitoring shows most headaches resolve within 4 hours of starting therapy.
Nausea
Affects 10-15% of patients and relates to reduced splanchnic blood flow during diuresis and vasodilation. Usually mild and transient, resolving within 2-4 hours. Occurs less in supine-positioned patients. Not related to direct drug irritation but rather systemic hemodynamic changes.
Management: Patient is typically NPO (nothing by mouth) during acute ICU phase. Anti-nausea medication (ondansetron) can be given if needed. Positioning change to semi-recumbent may help. Most nausea resolves spontaneously within 4-6 hours. As acute decompensation improves, nausea typically resolves.
Less Common
- •Elevated potassium levels
- •Worsening kidney function (transient)
- •Allergic reactions at injection site
- •Chest discomfort
- •Irregular heartbeat (arrhythmia)
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Ularitide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Ularitide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓Both work to relax blood vessels and reduce heart workload; complementary long-term therapy
- ✓Synergistic fluid removal; ularitide naturally enhances diuretic effects
- ✓Reduce heart rate and force while ularitide improves blood flow; balanced approach to heart recovery
With medications
- !Vasoconstrictors - Directly oppose ularitide's mechanism; could cause dangerous blood pressure swings
- !NSAIDs - Can reduce natriuretic peptide effectiveness and increase kidney injury risk
- !Certain Antiarrhythmics - May increase hypotension risk when combined with ularitide
With supplements
- ✓Multivitamins - Generally safe to take alongside Ularitide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Strong human trials
What to Expect
1988
What you might notice
- •Urodilatin discovered in human urine by Wolf-Georg Forssmann's research group
- •First identification of this natural kidney hormone
What's normal
- •Full integration of Ularitide into physiological systems is established
- •Long-term Ularitide response remains personalized to your physiology
- •Ularitide tolerance is well-maintained with consistent dosing
What's next
- →Maintain your established Ularitide protocol for sustained benefits
- →Continue periodic monitoring to confirm Ularitide efficacy
- →Review comprehensive Ularitide response with your provider
2000
What you might notice
- •Early clinical studies of ularitide (synthetic urodilatin) begin in Europe
- •Transition from research to human testing
What's normal
- •Ularitide has achieved stable, long-term homeostatic integration
- •Sustained efficacy of Ularitide remains consistent
- •Chronic Ularitide effects remain stable and predictable
What's next
- →Maintain your established Ularitide protocol for sustained benefits
- →Continue periodic monitoring to confirm Ularitide efficacy
- →Review comprehensive Ularitide response with your provider
2012
What you might notice
- •Major Phase 3 trial (ULARITIDE-AHEF) launched with 2,157 patients
- •Largest clinical test of ularitide for acute heart failure treatment
What's normal
- •Ularitide has achieved stable, long-term homeostatic integration
- •Sustained efficacy of Ularitide remains consistent
- •Chronic Ularitide effects remain stable and predictable
What's next
- →Maintain your established Ularitide protocol for sustained benefits
- →Continue periodic monitoring to confirm Ularitide efficacy
- →Review comprehensive Ularitide response with your provider
2015
What you might notice
- •Cardiorentis announces positive Phase 3 results for acute decompensated heart failure
- •Demonstrates safety and efficacy in large patient population
What's normal
- •Ularitide has achieved stable, long-term homeostatic integration
- •Sustained efficacy of Ularitide remains consistent
- •Chronic Ularitide effects remain stable and predictable
What's next
- →Maintain your established Ularitide protocol for sustained benefits
- →Continue periodic monitoring to confirm Ularitide efficacy
- →Review comprehensive Ularitide response with your provider
2016
What you might notice
- •Phase 3 trial completed;
- •FDA grants Fast Track designation
- •Recognition of therapeutic potential;
- •expedited review pathway
What's normal
- •Ularitide has achieved stable, long-term homeostatic integration
- •Sustained efficacy of Ularitide remains consistent
- •Chronic Ularitide effects remain stable and predictable
What's next
- →Maintain your established Ularitide protocol for sustained benefits
- →Continue periodic monitoring to confirm Ularitide efficacy
- →Review comprehensive Ularitide response with your provider
2018
What you might notice
- •Comprehensive meta-analysis published comparing ularitide to other emergency heart treatments
- •Scientific validation of ularitide's role in acute heart failure management
What's normal
- •Full therapeutic effects of Ularitide are well-characterized at this point
- •Maintenance of Ularitide's therapeutic effects is typical
- •Tolerance patterns with Ularitide are generally stable over months
What's next
- →Comprehensive assessment of Ularitide efficacy should be conducted
- →Discuss long-term continuation, cycling, or protocol modifications
- →Continue regular monitoring of relevant biomarkers or symptoms
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Ularitide over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis"
Mitrovic V, Forssmann WG, Schnitker J, 2018
Finding: Meta-analysis of 12 randomized controlled trials showed ularitide produced stronger improvements in pulmonary pressure and heart function compared to other vasoactive drugs. After just 6 hours of treatment, ularitide demonstrated significantly better hemodynamic results than placebo and other vasodilator treatments for acute heart failure patients.
View Study"Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies"
Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G, 2015
Finding: Comprehensive review documenting ularitide's development from laboratory research to human clinical trials. The natriuretic peptide showed promising results in early studies, establishing the scientific foundation and clinical evidence needed for its evaluation in larger Phase 3 trials for acute heart failure treatment.
View Study"New Pharmacotherapeutic Classes for the Management of Heart Failure: A Narrative Review"
Haryani A, Sangwan A, 2024
Finding: Recent 2024 review examined ularitide alongside other newer heart failure medications like vericiguat and serelaxin. The analysis highlighted ularitide's role as a novel natriuretic peptide therapy while noting the need for more long-term studies comparing these medications to standard treatments.
View Study"Short-Term Therapies for Treatment of Acute and Advanced Heart Failure"
Pollesello P, Ben Gal T, Bettex D, 2019
Finding: Review of short-acting therapies for acute and advanced heart failure that includes ularitide among vasodilator options. The article discusses ularitide's mechanism of action and clinical applications for rapidly improving heart failure symptoms in hospitalized patients.
View Study"Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis"
Dai H, Li H, Wang B, 2022
Finding: Network meta-analysis comparing 15 different acute heart failure drugs across 23 clinical trials with 17,097 patients showed all drugs had similar effectiveness and safety profiles. Ularitide was included in this comprehensive comparison, demonstrating comparable outcomes to other natriuretic peptides and vasodilators.
View StudyFrequently Asked Questions